Johnson & Johnson Guides FY26 Sales Above Estimates, Shares Rise

Johnson & Johnson (JNJ) announced fiscal year 2026 sales guidance above analyst expectations, citing strong performance in its pharmaceutical and medical devices divisions. The company projected revenue of $102.5 billion, surpassing the consensus estimate of $100.3 billion, as demand for key products like Stelara and Simponi remains robust. The guidance update, released on January 21, 2026, reflects improved volume growth and pricing power, particularly in global markets. JNJ also reaffirmed its commitment to a 4%–6% annual dividend increase and returned $7.8 billion to shareholders through buybacks in FY25. The stock rose 1.8% in after-hours trading following the announcement.